The efficacy of thymosin in the treatment of chronic hepatitis B virus infection: a meta-analysis

Authors


Dr J. J.-Y. Sung, Department of Medicine and Therapeutics, 9/F Prince of Wales Hospital, 30–32 Ngan Shing Street, Shatin, Hong Kong. E-mail: joesung@cuhk.edu.hk

Abstract

Background:

Trials of thymosin treatment in chronic hepatitis B virus infection have been small and the results have been inconsistent.

Aim:

To conduct a meta-analysis to evaluate the efficacy of thymosin treatment in chronic hepatitis B virus infection.

Methods:

Randomized controlled trials comparing thymosin for over 24 weeks vs. placebo (or usual care) in the treatment of chronic hepatitis B virus infection were identified through MEDLINE, EMBASE and the Cochrane Register of Clinical Trials. Biochemical (normalization of transaminases) and virological (loss of hepatitis B virus DNA and hepatitis B e antigen) responses were analysed using the intention-to-treat method. The odds ratio was used to measure the magnitude of the efficacy.

Results:

Five trials (353 patients) were identified. The odds ratio (95% confidence interval) of the virological response of thymosin over placebo at the end of treatment, 6 months post-treatment and 12 months post-treatment were 0.56 (0.2–1.52), 1.67 (0.83–3.37) and 2.67 (1.25–5.68), respectively. There was an increasing trend of the virological response with time since the cessation of thymosin treatment (P=0.02). There was no difference in the biochemical response between the thymosin and placebo groups at the end of treatment, 6 months post-treatment and 12 months post-treatment.

Conclusions:

Thymosin is effective in suppressing viral replication in chronic hepatitis B virus infection, but the effect is delayed until 12 months after the cessation of treatment.

Ancillary